Bisoprolol Aurobindo of the tab. of p/o of 10 mg No. 28

tablets Bisoprolol Aurobindo are shown at treatment of stable chronic heart failure with systolic dysfunction of a left ventricle, in a combination with APF inhibitors, diuretics, in case of need - cardiac glycosides.

Structure

Active ingredient: bisoprolol;

1 tablet, coated, contains - 10 mg of a bisoprolol of the fumarat;

Excipients: microcrystalline cellulose, calcium hydrophosphate anhydrous, silicon dioxide colloidal, krospovidon, magnesium stearate, Opadry white 0ZV28796 (gipromelloza, titan dioxide (E 171), macrogoal 400).

Contraindication

• hypersensitivity to a bisoprolol or other components of drug;
• acute heart failure or heart failure in a condition of a decompensation demanding inotropic therapy;
• cardiogenic shock;
• blockade of II and III degree;
• sick sinus syndrome;
• sinuatrial blockade;
• symptomatic bradycardia;
• symptomatic arterial hypotension;
• severe form of bronchial asthma or severe form of a chronic obstructive disease of lungs;
• severe form of disturbance of peripheric circulation and Reynaud's syndrome;
• pheochromocytoma, was not treated;
• metabolic acidosis.

Route of administration

Drug Bisoprolol Aurobindo should be taken in the morning (inclusion in meal time is possible), without chewing, washing down with liquid.

Standard therapy of chronic heart failure: APF inhibitors (or blockers of receptors of angiotensin in case of intolerance of APF inhibitors), blockers of β-adrenoceptors, diuretics and in case of need cardiac glycosides. Patients have to have a stable state (without acute heart failure) in an initiation of treatment bisoprololy.

Attending physician has to have experience of treatment of chronic heart failure.

Perhaps tranzitorny deterioration in heart failure, arterial hypotension or bradycardia during the period of titration and after it.

Feature of use

Pregnant women

only when the expected advantage for mother exceeds potential risk for a fruit. Children

it is not recommended by

to p.

Drivers

In some cases medicament can affect ability to run motor transport or to work with mechanisms.

Overdose

At overdose (for example, a daily dose of 15 mg instead of 7.5 mg) recorded cases of development of atrioventricular block of the III degree, bradycardia and dizziness. Frequent signs of overdose by β-blockers is bradycardia, arterial hypotension, a bronchospasm, an acute heart failure and a hypoglycemia.

At overdose stop medicament treatment and carry out the supporting and symptomatic therapy. According to expected pharmacological action and based on recommendations for other β-blockers, it is necessary to consider the following general actions.

Side effects

• from a cardiovascular system. Bradycardia. Deterioration in heart failure is frequent.
• from nervous system. Dizziness, headache.
• from a digestive tract. Often gastrointestinal disorders, such as nausea, vomiting, diarrhea, constipation.
• from the vascular system. The cryesthesia or numbness in extremities, arterial hypotension is frequent.

Interaction

Combination which are not recommended to be applied.

Antagonists of calcium (groups of verapamil, to a lesser extent - diltiazem): negative impact on sokratitelny function of a myocardium and AV conductivity. Administration of verapamil at the patients accepting β-blockers can lead to the profound arterial hypotension and AV of blockade.

Antiarrhytmic means of the I class (for example quinidine, Disopyramidum, lidocaine, Phenytoinum, flekainid, propafenon): potentiation of effect of AV conductivity and strengthening of negative inotropic effect is possible.

Hypotensive medicaments of the central action (clonidine, Methyldopum, guanfatsin, moksinidin, rilmenidin): deterioration in a course of heart failure owing to decrease in the central sympathetic tone (decrease in heart rate and warm emission, a vazodilatation) is possible. Sudden medicament withdrawal, especially if precedes it cancellation of blockers of β-adrenoceptors, can increase risk of developing of ricochet hypertensia.

to Store

out of children's reach at a temperature not above 25 °C.

Expiration date - 2 years.